Table 2.

Physical analysis of urine in various treatment groups.

Treatment (mg/kg)	pH	Specific gravity	RBC/µl	WBC/µl	Urea (mg/dl)
Control	7.110 ± 0.050b	1.042 ± 0.011b	0.046 ± 0.01b	15.83 ± 0.291b	12.77 ± 0.590b
DOX	6.020 ± 0.032a	1.487 ± 0.019a	13.35 ± 0.05a	75.17 ± 0.318a	41.37 ± 0.876a
AHE alone	7.107 ± 0.029b	1.041 ± 0.012b	0.047 ± 0.011b	15.77 ± 0.233b	12.57 ± 0.484b
DOX + AHE (200)	6.78 ± 0.103a**,b,d*	1.19 ± 0.02a,b,d	5.930 ± 0.09a,b,d	40.67 ± 0.278a,b,d	24.55 ± 0.553a,b,d
DOX + AHE (400)	7.057 ± 0.024b,c*	1.06 ± 0.02b,c**	0.647 ± 0.022a,b,c	16.07 ± 0.120b,c	14.43 ± 0.338b,c
DOX + Sily	7.053 ± 0.038b	1.053 ± 0.020b	0.618 ± 0.014a,b	16.17 ± 0.260b	14.37 ± 0.318b

Values expressed as mean ± SEM. a: Significance at p < 0.0001 Vs. control group, b: Significance at p < 0.0001 Vs. Doxorubicin (DOX) group, c: Significance at p < 0.0001 of DOX + AHE 400 mg/kg group Vs. DOX + AHE 200 mg/kg group. d: Significance at p < 0.0001 of AHE co-treatment groups Vs DOX + Sily group. ^**: Significant difference at p < 0.05 and p < 0.001 respectively. Non-significant difference (p > 0.05) was recorded between control and AHE alone treated group in all parameters. (One way ANOVA followed by Tukey’s multiple comparison tests). Sily-Silymarin.